IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#2195
Positioning
Market Dominance
Finance, Insurance, And Real Estate
Trading
$379M
Mark Gerhard
We are a blank check company incorporated as a Cayman Islands exempted company and incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Our executive offices are located at 667 Madison Avenue, 5th Floor, New York, NY.
Headcount
—
HQ Base
NEW YORK, New York
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$SII SPROTT INC. | 75 | 91 | 87 | 98 | - | - | 15.7% | 12.8% | 48.9% | 37.0% | 28.8% | 14.9% | 2.5% | 0.0x | $1.1B | VS | |
$PUK PRUDENTIAL PLC | 73 | 88 | 97 | 80 | - | - | 13.2% | 1.4% | 100.0% | 97.0% | 23.8% | 11.8% | 2.7% | 5.0x | $21.5B | VS | |
$NMR NOMURA HOLDINGS INC | 72 | 81 | 92 | 87 | - | - | 9.9% | 0.6% | 84.5% | 70.0% | 7.3% | 14.9% | 0.0% | 923.0x | $18.3B | VS | |
$PSLV Sprott Physical Silver Trust | 69 | 82 | 80 | 98 | - | - | 17.3% | 17.7% | 100.0% | 100.0% | 100.0% | 1643.8% | 0.0% | 0.0x | $5.0B | VS | |
$UFCS UNITED FIRE GROUP INC | 68 | 81 | 93 | 76 | 5.0x | 3.5x | 13.2% | 4.1% | 99.9% | 14.7% | 11.1% | 9.2% | 2.1% | 16.0x | $775M | VS | |
$SLF SUN LIFE FINANCIAL INC | 68 | 83 | 95 | 63 | - | - | 12.6% | 0.9% | 32.0% | 31.3% | 7.9% | -12.9% | 4.3% | 24.0x | $37.8B | VS | |
$CBOE Cboe Global Markets, Inc. | 68 | 75 | 63 | 77 | 21.3x | 15.7x | 24.0% | 13.7% | 41.7% | 32.4% | 26.4% | 8.2% | 1.1% | 30.0x | $25.7B | VS | |
$PHYS Sprott Physical Gold Trust | 67 | 64 | 82 | 91 | - | - | 22.5% | 22.8% | 101.8% | 100.0% | 100.0% | 138.9% | 0.0% | 0.0x | $8.4B | VS | |
$VTMX Vesta Real Estate Corporation, S.A.B. de C.V. | 67 | 69 | 77 | 80 | - | - | 8.8% | 5.8% | 98.7% | 75.7% | 88.5% | 17.6% | 4.3% | 34.0x | $2.2B | VS | |
$GLDM World Gold Trust | 66 | 54 | 85 | 92 | 11.3x | 11.3x | - | 27.1% | 100.0% | 98.9% | 459.9% | 333.4% | 0.0% | 0.0x | $43.7B | VS | |
$ALF Centurion Acquisition Corp. | 49 | 32 | 35 | 34 | 29.8x | - | - | 4.2% | - | - | - | - | 0.0% | - | $379M | ||
| SECTOR BENCH | - | - | - | - | - | 11.9x | 7.8x | 8.9% | 1.2% | 76.5% | 17.0% | 21.5% | 10.8% | 1.9% | 0.5x | - | REF |
Centurion Acquisition Corp. (ALF) receives a "Reduce" rating with a composite score of 48.8/100. It ranks #2195 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Asset base utilization
Direct cash return
Mark Gerhard
Chief Executive Officer
32
32
95
Audit Verdict: Average governance indicators based on financial metrics.
No recent insider transactions available for ALF
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
Low volatility — smoother ride and historically better risk-adjusted returns
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for ALF.
View All RatingsInsufficient data for Financial Analysis
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 32 | 53 | -21DRAG |
| MOMENTUM | 34 | 30 | +4NEUTRAL |
| VALUATION | 35 | 33 | +2NEUTRAL |
| INVESTMENT | 32 | 45 | -13DRAG |
| STABILITY | 95 | 96 | -1NEUTRAL |
| SHORT INT | 84 | 93 | -9DRAG |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
Insufficient data for ROIC calculation
GM N/A vs sector 77%, OM N/A vs sector 17%
Capital turnover N/A
Rev growth N/A
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Centurion Acquisition Corp. receives a Reduce rating from our analysis, with a composite score of 48.8/100 and 2 out of 5 stars, ranking #2195 out of 7,333 stocks. ALF's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
ALF's quality score of 32/100 is below average, suggesting challenges with profitability or capital efficiency. Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 35/100, ALF appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/E ratio of 29.77x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
Centurion Acquisition Corp.'s investment score of 32/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of 4.2% (sector: 1.2%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
ALF is currently showing below-average momentum at 34/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth data is not currently available, while a beta of 0.01 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
Centurion Acquisition Corp. earns an excellent stability score of 95/100, reflecting low price volatility and a conservatively managed balance sheet. Key stability metrics include a beta of 0.01. Stocks with this level of stability tend to act as portfolio anchors, providing downside protection during market corrections while still participating in broad market advances.
ALF's short interest factor score of 84/100 indicates very low short selling activity relative to peers — a positive signal suggesting institutional investors see limited near-term downside. Specific risk factors include small-cap liquidity risk. As a small-cap company with a market capitalization of $379M, Centurion Acquisition Corp. benefits from the generally lower volatility and deeper liquidity associated with its size class.
Centurion Acquisition Corp. is a small-cap company in the Finance, Insurance, And Real Estate sector, ranked #0 of 50 in its sector (100th percentile) and #2195 of 7,333 overall (70th percentile). This top-quartile standing reflects exceptional competitive strength relative to Finance, Insurance, And Real Estate peers.
While ALF currently exhibits a REDUCE profile, superior opportunities exist within the FINANCE, INSURANCE, AND REAL ESTATE sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Finance, Insurance, And Real Estate Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Quality (32) would have the largest impact on the composite score.
Div. Yield 100% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate Centurion Acquisition Corp. (ALF) as a Reduce with a composite score of 48.8/100 at a current price of $10.74. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential and elevated risk of underperformance relative to peers over the next 12 months.
The rating is primarily driven by strength in stability (95th percentile) and value (35th percentile), which together account for the majority of the composite score. Offsetting weakness in investment (32th percentile) and quality (32th percentile) tempers our overall conviction. We assign a No Moat rating (28/100), Low uncertainty, and Poor capital allocation.
Key items to watch: momentum to confirm whether the current price trend has legs. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
Centurion Acquisition Corp. holds a top-quartile position (#0 of 50) within the Finance, Insurance, And Real Estate sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 48.8/100 places it at rank #2195 in our full 7,333-stock universe. At $379M in market capitalization, Centurion Acquisition Corp. is a small-cap player in the Finance, Insurance, And Real Estate space, which limits certain scale advantages but may allow for more agile strategic execution.
Momentum indicators (34th percentile) suggest caution regarding the near-term price trend. Revenue growth data is unavailable, limiting our ability to confirm whether momentum is fundamentally supported.
Margin data is not available for Centurion Acquisition Corp., which limits our assessment of the company's cost structure and operating efficiency. We rely on factor-based signals to infer business quality in the absence of detailed margin data.
At a current price of $10.74, Centurion Acquisition Corp. is trading at a premium to fundamental value. Our value factor score of 35/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at a P/E of 29.8x (a 150% premium to the sector median of 11.9x). The above-sector P/E multiple suggests the market is pricing in superior growth or quality, which our analysis finds only partially justified by current fundamentals.
The stock may offer contrarian value if near-term headwinds prove transitory — the current weakness in factor scores may reverse if business fundamentals stabilize.
The Reduce rating (composite 48.8/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Weak momentum (34th percentile) suggests institutional selling pressure and unfavorable technical dynamics that may persist.
Below-average quality (32th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
Elevated short interest (84th percentile) indicates that sophisticated market participants are betting against the stock.
We assign a Low uncertainty rating to Centurion Acquisition Corp.. The company exhibits strong financial stability with a beta of 0.01, and a stability factor in the 95th percentile. The predictable nature of the business model and solid financial position reduce the range of potential outcomes, giving us confidence in our fair value estimate.
Specific risk factors that inform our assessment include: weak quality scores (32th percentile); low beta of 0.01 — while defensive, this may indicate limited upside participation in bull markets. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 95th percentile and quality factor at the 32th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: above-average stability (95th percentile) suggests predictable business dynamics. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile is favorable for long-term investors.
We rate Centurion Acquisition Corp.'s capital allocation as Poor. Key concerns include suboptimal returns on capital. Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — Centurion Acquisition Corp. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, Centurion Acquisition Corp. receives a Reduce rating with a composite score of 48.8/100 (rank #2195 of 7,333). Our quantitative framework assigns a No Moat (28/100, trend: stable), Low uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 45/100.
Our analysis does not support a constructive view on Centurion Acquisition Corp. at this time. The combination of limited competitive advantages, low uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign Centurion Acquisition Corp. a meaningful economic moat, scoring 28/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, growth durability, reached only 10.5/20.
The strongest moat sources are growth durability (10.5/20) and margin superiority (10/20). Rev growth N/A. GM N/A vs sector 77%, OM N/A vs sector 17%. These pillars form the core of Centurion Acquisition Corp.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (0/20) and financial resilience (2.5/20). Capital turnover N/A. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect Centurion Acquisition Corp.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers are not clearly identifiable from current fundamentals. This may reflect a company in transition, a cyclical downturn, or structural challenges in the business model. We assign a quality factor of 32/100 which further underscores our concern regarding earnings sustainability.
Return metrics include ROA of 4.2%. Relative to the Finance, Insurance, And Real Estate sector, sector comparison data is limited.
Balance sheet data is limited, restricting our assessment of financial resilience. Investors should seek additional disclosure on leverage and liquidity before forming a complete view of financial health.
Above 50MA
37.18%
Net New Highs
+51081
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., January 26, 2026--United Therapeutics Corporation (Nasdaq: UTHR) today announced positive results from its phase 1 study of miroliverELAP®, an external liver assist product, in patients with acute forms of liver failure, acute-on-chronic liver failure, and severe acute alcoholic hepatitis, collectively called acute liver failure (ALF).2
NEW YORK, July 29, 2024 (GLOBE NEWSWIRE) -- Centurion Acquisition Corp. (Nasdaq: ALFUU) (the “Company”) announced that holders of the units sold in the Company’s initial public offering of 28,750,000 units, which includes 3,750,000 units issued pursuant to the exercise by the underwriters of their overallotment option, completed on June 12, 2024 (the “Offering”), may elect to separately trade the Class A ordinary shares and warrants included in the units commencing on or about August 1, 2024. An

Gainers Applied Genetic Technologies Corporation (NASDAQ: AGTC) climbed 62.4% to close at $0.39. Syncona disclosed that it will acquire Applied Genetic Technologies Corporation. Vaxcyte, Inc. (NASDAQ: PCVX) shares surged 60.4% to close at $33.00 on Monday after the company announced positive topline results from the Phase 1/2 clinical proof-of-concept study evaluating the safety, tolerability and immunogenicity of VAX-24. Mullen Automotive, Inc. (NASDAQ: MULN) climbed 32.9% to close at $0.50 after the company announced it has secured exclusive sales, distribution and branding rights to the I-GO, which is fully EU Standard homologated and certified for sale in select European markets. Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) climbed 24.8% to close at $0.4741. Motus GI Holdings, Inc. (NASDAQ: MOTS) climbed 23.1% to close at $1.97 after the company announced clinical data for Pure-Vu EVS in three poster presentations at the American College of Gastroenterology 2022 Annual Scientific Meeting. KULR Technology Group, Inc. (NASDAQ: KULR) gained 22.7% to close at $1.84. Novonix Limited (NASDAQ: NVX) climbed 22.1% to close at $7.57. NOVONIX was recently selected for $150 million grant from U.S. Department of Energy. SOBR Safe, Inc. (NASDAQ: SOBR) gained 21.1% to close at $3.90. BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) gained 20.6% to close at $2.8945. BYND Cannasoft Enterprises entered into a consulting service with Matrix Medika, a developer of medical systems specialized in assisting companies in obtaining regulatory approval for medical devices under development. Dermata Therapeutics, Inc. (NASDAQ: DRMA) jumped 18.1% to close at $0.77. NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) jumped 17.4% to close at $1.69. uCloudlink Group Inc. (NASDAQ: UCL) surged 17% to close at $0.8070. EpicQuest Education Group International Limited (NASDAQ: EEIQ) gained 16.7% to close at $1.14. Avis Budget Group, Inc. (NASDAQ: CAR) gained 16.6% to close at $220.83 after analysts at JP Morgan upgraded their rating of the stock from Neutral to Overweight. Sutro Biopharma, Inc. (NASDAQ: STRO) rose 14.7% to close at $6.47. ASAP, Inc. (NASDAQ: WTRH) shares gained 13.2% to close at $0.16. ASAP.com recently launched home & office delivery in New York City. Helbiz, Inc. (NASDAQ: HLBZ) jumped 12.7% to close at $0.31. Eve Holding, Inc. (NASDAQ: EVEX) gained 11.9% to close at $10.95. Scholastic Corporation (NASDAQ: SCHL) shares gained 10.4% to close at $37.13 after the company announced an up to $75 million buyback through a modified "Dutch Auction" tender offer. NantHealth, Inc. (NASDAQ: NH) jumped 10.3% to close at $0.3612. Marathon Digital Holdings, Inc. (NASDAQ: MARA) gained 10.3% to close at $12.90. Covenant Logistics Group, Inc. (NASDAQ: CVLG) climbed 9.4% to close at $36.86. Stephens & Co. maintained Covenant Logistics with an Equal-Weight and raised the price target from $35 to $40. Myovant Sciences ...

Gainers Vaxcyte, Inc. (NASDAQ: PCVX) shares jumped 65% to $33.96 after the company announced positive topline results from the Phase 1/2 clinical proof-of-concept study evaluating the safety, tolerability and immunogenicity of VAX-24. Healthcare Triangle, Inc. (NASDAQ: HCTI) gained 54.8% to $0.6000. Applied Genetic Technologies Corporation (NASDAQ: AGTC) climbed 54.1% to $0.3701. Syncona disclosed that it will acquire Applied Genetic Technologies Corporation. Motus GI Holdings, Inc. (NASDAQ: MOTS) gained 40% to $2.2450 after the company announced clinical data for Pure-Vu EVS in three poster presentations at the American College of Gastroenterology 2022 Annual Scientific Meeting. Mullen Automotive, Inc. (NASDAQ: MULN) rose 31.8% to $0.4957 after the company announced it has secured exclusive sales, distribution and branding rights to the I-GO, which is fully EU Standard homologated and certified for sale in select European markets. Enservco Corporation (NYSE: ENSV) gained 21.3% to $2.4499. The company, last week, posted a profit for the first quarter. Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) rose 19.8% to $0.4551. Novonix Limited (NASDAQ: NVX) gained 19.6% to $7.42. NOVONIX was recently selected for $150 million grant from U.S. Department of Energy. Kaspien Holdings Inc. (NASDAQ: KSPN) rose 17.1% to $1.30. Provident Acquisition Corp. (NASDAQ: PAQC) surged 15.6% to $8.92. Scholastic Corporation (NASDAQ: SCHL) shares gained 13.9% to $38.31 after the company announced an up to $75 million buyback through a modified "Dutch Auction" tender offer. Dermata Therapeutics, Inc. (NASDAQ: DRMA) jumped 12% to $0.73. Tian Ruixiang Holdings Ltd (NASDAQ: TIRX) gained 11.6% to $0.6196. NantHealth, Inc. (NASDAQ: NH) jumped 11.2% to $0.3642. Avis Budget Group, Inc. (NASDAQ: CAR) gained 10.6% to $209.59 after analysts at JP Morgan upgraded their rating of the stock from Neutral to Overweight. Pearson plc (NYSE: PSO) rose 9.9% to $10.95. Covenant Logistics Group, Inc. (NASDAQ: CVLG) gained 9.1% to $36.76. Stephens & Co. maintained Covenant Logistics with an Equal-Weight and raised the price target from $35 to $40. Myovant Sciences Ltd. (NYSE: MYOV) shares rose 9% to $26.74 after the company agreed to be acquired by Japanese pharmaceutical company Sumitomo Pharma’s unit Sumitovant Biopharma in a $1.7 billion deal. Inozyme Pharma, Inc. (NASDAQ: INZY) surged 6.8% to $2.37 ASAP, Inc. (NASDAQ:

Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) jumped 89.3% to close at $58.92 on Friday. Altamira Therapeutics Ltd. (NASDAQ: CYTO) climbed 58.6% to close at $0.5197 on Friday after the company announced divestiture of its inner ear development assets. Missfresh Limited (NASDAQ: MF) gained 57.5% to close at $2.52. Enservco Corporation (NYSE: ENSV) climbed 37.4% to close at $2.02. Kaleyra, Inc. (NYSE: KLR) gained 24.9% to close at $0.8616. Veris Residential, Inc. (NYSE: VRE) surged 23.3% to close at $15.31 after Kushner Companies made an offer to acquire the company for $16 per share. Matinas BioPharma Holdings, Inc. (NYSE: MTNB) rose 22.2% to settle at $0.8538. Matinas BioPharma announced interim data from the Phase 2 EnACT trial of MAT2203 for the treatment of cryptococcal meningitis, exceeding primary endpoint threshold. Candel Therapeutics, Inc. (NASDAQ: CADL) gained 21.6% to close at $1.80. Energy Focus, Inc (NASDAQ: EFOI) shares climbed 21.5% to close at $0.4900. Energy Focus, last month, named Lesley Matt as CEO. Leju Holdings Limited (NYSE: LEJU) gained 21.1% to settle at $1.61. Rail Vision Ltd. (NASDAQ: RVSN) gained 20.5% to close at $0.5898. Rockley Photonics Holdings Limited (NYSE: RKLY) surged 20.1% to settle at $0.6262. The Boston Beer Company, Inc. (NYSE: SAM) jumped 19.7% to close at $402.28 after the company reported better-than-expected Q3 adjusted EPS and sales results. MacroGenics, Inc. (NASDAQ: MGNX) rose 19.4% to close at $4.80. TuanChe Limited (NASDAQ: TC) climbed 19.1% to settle at $7.87. Zentek Ltd. (NASDAQ: ZTEK) gained 18.9% to close at $1.57. Yunji Inc. (NASDAQ: YJ) rose 18.6% to close at $1.02. Snow Lake Resources Ltd. (NASDAQ: LITM) climbed 18.5% to close at $2.43. Biohaven Ltd. (NYSE: BHVN) gained 17.7% to close at $14.08. Biohaven reported pricing of public offering of 25 million common shares at a price of $10.50 per share. Amprius Technologies, Inc. (NASDAQ: AMPX) climbed 17.6% to close at $11.11. Amprius Technologies was awarded a $50 million cost-sharing grant from the U.S. Department of Energy's Office of Manufacturing and Energy Supply Chains. Healthcare Triangle, Inc. (NASDAQ: HCTI) gained 17.2% to close at $0.3875. AppTech Payments Corp. (NASDAQ: APCX) gained 16.4% to settle at $0.8849. Pacific Biosciences of California, Inc. (NASDAQ: PACB) climbed 16.3% to close at $7.77. Biotricity, Inc. (NASDAQ: BTCY) rose 15.7% to close at $1.10. uCloudlink Group Inc. (NASDAQ: ...